Chakrabarti M, Cheng K T, Spicer K M, Kirsch W M, Fowler S D, Kelln W, Griende S, Nehlsen-Cannarella S, Willerson R, Spicer S S
Department of Hospital Pharmacy, Medical University of South Carolina, Charleston 29425, USA.
Nucl Med Biol. 1995 Aug;22(6):693-7. doi: 10.1016/0969-8051(95)00008-l.
Monoclonal antibodies have been raised against Ama isolated from human and experimental atherosclerotic plaque. 131I-Ama-MoAb in the whole antibody form was injected into normal NZW rabbits and Watanabe hyperlipidemic rabbits. Biodistribution studies showed that atheromatous aortas had a significantly higher (5-7X) uptake of 131I-Ama-MoAb than that of normal aortas. However, 131I-Ama-MoAb was cleared very slowly from atherosclerotic rabbits. As a result, atheromas could not be identified by imaging because of the low target to non-target ratios.
已经制备出针对从人类和实验性动脉粥样硬化斑块中分离出的抗巨噬细胞抗体（Ama）的单克隆抗体。将全抗体形式的131I-Ama-单克隆抗体注入正常的新西兰白兔和渡边高脂血症兔体内。生物分布研究表明，动脉粥样硬化主动脉对131I-Ama-单克隆抗体的摄取量显著高于正常主动脉（高5至7倍）。然而，131I-Ama-单克隆抗体从动脉粥样硬化兔体内清除非常缓慢。因此，由于靶与非靶比值低，无法通过成像识别动脉粥样瘤。
